Schwab Charles Investment Management Inc. cut its position in Anika Therapeutics Inc (NASDAQ:ANIK) by 6.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,865 shares of the biotechnology company’s stock after selling 4,414 shares during the period. Schwab Charles Investment Management Inc. owned 0.45% of Anika Therapeutics worth $3,821,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of ANIK. SG Americas Securities LLC purchased a new position in Anika Therapeutics during the third quarter worth approximately $118,000. Victory Capital Management Inc. raised its position in Anika Therapeutics by 17.6% in the second quarter. Victory Capital Management Inc. now owns 4,060 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 608 shares during the period. BNP Paribas Arbitrage SA raised its position in Anika Therapeutics by 3.0% in the second quarter. BNP Paribas Arbitrage SA now owns 4,315 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 126 shares during the period. Stevens Capital Management LP purchased a new stake in Anika Therapeutics in the third quarter valued at $222,000. Finally, Miles Capital Inc. purchased a new stake in Anika Therapeutics in the second quarter valued at $232,000. 84.91% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Richard Hague sold 5,250 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $54.48, for a total transaction of $286,020.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Charles H. Sherwood sold 22,228 shares of the company’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $60.06, for a total value of $1,335,013.68. Following the transaction, the chief executive officer now directly owns 158,297 shares of the company’s stock, valued at $9,507,317.82. The disclosure for this sale can be found here. Corporate insiders own 6.57% of the company’s stock.
Anika Therapeutics Inc (NASDAQ:ANIK) opened at $59.03 on Friday. Anika Therapeutics Inc has a one year low of $41.64 and a one year high of $60.29. The company has a market capitalization of $865.50, a price-to-earnings ratio of 27.71, a P/E/G ratio of 3.58 and a beta of 1.44.
Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.05. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The firm had revenue of $27.18 million during the quarter, compared to analysts’ expectations of $27.44 million. During the same period in the previous year, the firm posted $0.59 EPS. Anika Therapeutics’s revenue for the quarter was up 5.4% on a year-over-year basis. research analysts anticipate that Anika Therapeutics Inc will post 1.9 EPS for the current year.
A number of research firms have commented on ANIK. Barrington Research restated a “buy” rating and issued a $57.00 target price on shares of Anika Therapeutics in a research report on Thursday, December 28th. BidaskClub upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/21/anika-therapeutics-inc-anik-shares-sold-by-schwab-charles-investment-management-inc.html.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.